Literature DB >> 7706306

Detection of a novel transcription factor for the A alpha fibrinogen gene in response to interleukin-6.

Z Liu1, G M Fuller.   

Abstract

The three fibrinogen genes belong to the class II hepatic acute phase proteins that are regulated in part by members of the interleukin-6 (IL-6) family of cytokines and glucocorticoids. The common DNA sequence that characterizes this group of proteins is a hexanucleotide CTGGGA residing in the promoter regions of these genes. Investigations of IL-6 control of the A alpha fibrinogen gene by electrophoretic mobility shift assays using a 30-base pair DNA probe containing the CTGGGA element revealed that a novel protein is associated with this site during non-IL-6-stimulated conditions. Sensitive time-course studies of IL-6 stimulation using primary hepatocyte cultures, high resolution polyacrylamide gel electrophoresis, and site-directed mutagenesis show that upon IL-6 stimulation of hepatocytes, this DNA binding protein transiently leaves the CTGGGA site and binds 12 base pairs down-stream but then begins to re-associate with the original DNA site at 1 h and is completed by 2 h. A recently characterized and cloned IL-6-activated transcription factor, Stat-3, which has been reported to bind a CT-GGGAA site in the alpha-2 macroglobulin gene, another member of the class II acute phase proteins, does not bind to the CTGGGA sequence in the A alpha fibrinogen gene. These findings reveal the presence of a previously undefined IL-6-regulated event, which involves a new DNA binding protein and demonstrates for the first time additional details of the kinetics of IL-6 control of fibrinogen gene expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7706306     DOI: 10.1074/jbc.270.13.7580

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  7 in total

1.  Two variants of quantitative reverse transcriptase PCR used to show differential expression of alpha-, beta- and gamma-fibrinogen genes in rat liver lobes.

Authors:  J Zhang; M Desai; S E Ozanne; C Doherty; C N Hales; C D Byrne
Journal:  Biochem J       Date:  1997-02-01       Impact factor: 3.857

2.  Identification and characterization of endonuclein binding proteins: evidence of modulatory effects on signal transduction and chaperone activity.

Authors:  Maja Ludvigsen; Morten Østergaard; Henrik Vorum; Christian Jacobsen; Bent Honoré
Journal:  BMC Biochem       Date:  2009-12-22       Impact factor: 4.059

3.  Essential role of STAT3 in the control of the acute-phase response as revealed by inducible gene inactivation [correction of activation] in the liver.

Authors:  T Alonzi; D Maritano; B Gorgoni; G Rizzuto; C Libert; V Poli
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

4.  Interleukin-6-induced STAT3 and AP-1 amplify hepatocyte nuclear factor 1-mediated transactivation of hepatic genes, an adaptive response to liver injury.

Authors:  J I Leu; M A Crissey; J P Leu; G Ciliberto; R Taub
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

5.  The lipopolysaccharide-binding protein is a secretory class 1 acute-phase protein whose gene is transcriptionally activated by APRF/STAT/3 and other cytokine-inducible nuclear proteins.

Authors:  R R Schumann; C J Kirschning; A Unbehaun; H P Aberle; H P Knope; N Lamping; R J Ulevitch; F Herrmann
Journal:  Mol Cell Biol       Date:  1996-07       Impact factor: 4.272

6.  Interleukin-6-specific activation of the C/EBPdelta gene in hepatocytes is mediated by Stat3 and Sp1.

Authors:  C A Cantwell; E Sterneck; P F Johnson
Journal:  Mol Cell Biol       Date:  1998-04       Impact factor: 4.272

7.  Interaction between fibrinogen and IL-6 genetic variants and associations with cardiovascular disease risk in the Cardiovascular Health Study.

Authors:  Cara L Carty; Patrick Heagerty; Susan R Heckbert; Gail P Jarvik; Leslie A Lange; Mary Cushman; Russell P Tracy; Alexander P Reiner
Journal:  Ann Hum Genet       Date:  2010-01       Impact factor: 1.670

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.